Novartis Pharmaceuticals announced today that it will appeal the U.S. Court of Appeals for the Federal Circuit’s (CAFC’s) June decision invalidating its patent for a dosing regimen for its multiple sclerosis drug Gilenya to the U.S. Supreme Court, after the CAFC denied its request to rehear the case. The CAFC in June vacated a different three-judge panel’s January opinion upholding Novartis’ U.S. Patent No. 9,187,405. In the original ruling, Chief Judge Moore had dissented from the majority; in the rehearing, Moore authored the opinion vacating the January decision, with Judge Linn dissenting.
Recent Posts
- Other Barks and Bites for Friday, April 26: World Intellectual Property Day Celebrated Around the Globe; China Tops List for AI Patents Granted; EPO Releases Cleantech Study on World IP Day
- Celebrating World IP Day: Is the Innovative Future Sustainable?
- The Rise of IP Lawsuits When Posting Images: How to Navigate and Avoid Copyright Infringement Issues
- The SEP Couch: Lyse Brillouet on Managing SEPs and Open Standards
- Unveiling The Untapped Potential of Brazil’s Solar Energy Market